Meningococcal disease in international travel: Vaccine strategies

Journal of Travel Medicine

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Wilder Smith, Annelies ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AFRICA; ASIA; AUSTRALIA; CHILD; DISEASE TRANSMISSION; ENDEMIC DISEASE; EPIDEMIC; EUROPE; HIGH RISK POPULATION; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NONHUMAN; RELIGIOUS GROUP; REVIEW; SAUDI ARABIA; SEROTYPE; TRAVEL; UNITED STATES; VACCINATION;

EID: 17844401218     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2005.12054     Document Type: Review

References (86)

1. Steffen R, Dupont H, Wilder-Smith A, eds. Manual of travel medicine and health, 2nd edn. Hamilton: BC Decker, 2003.
2. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378-1388.
3. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996; 15:967-978; quiz 979.
4. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99:591-601.
5. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353:941-942.
6. Conyn-van Spaendonck MA, Reintjes R. Spaujaard L, et al. Meningococcal carriage in relation to an outbreak of invasive disease due to Neisseria meningitidis serogroup C in the Netherlands. J Infect 1999; 39:42-48.
7. Wilder-Smith A, Barkham TM, Earnest A, Paton NI. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ 2002; 325:365-366.
8. Riordan T, Cartwright K, Andrews N, et al. Acquisition and carriage of meningococci in marine commando recruits. Epidemiol Infect 1998; 121:495-505.
9. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000; 320:846-849.
10. Wilder-Smith A. W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. Int J Antimicrob Agents 2003; 21:112-115.
11. Moore PS, Toole MJ, Nieburg P, et al. Surveillance and control of meningococcal meningitis epidemics in refugee populations. Bull World Health Organ 1990; 68:587-596.
12. Cuevas L, Kazembe P, Mughogho G, et al. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 1995; 171:728-731.
13. Simmons G, Jones N, Calder L. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. J Antimicrob Chemother 2000; 45:909-911.
14. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-1508.
15. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180: 1894-1901.
16. Djibo S, Nicolas P, Alonso JM, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003; 8:1118-1123.
17. Brandstetter RD, Blair RJ, Roberts RB. Neisseria meningitidis serogroup W 135 disease in adults. JAMA 1981; 246:2060-2061.
18. Noah N, Conolly M. Surveillance of bacterial meningitis in Europe 1995. London: King's European Meningitis Surveillance Unit, 1996.
19. Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat Q 1997; 50:170-177.
20. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-1497.
21. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998; 177:497-500.
22. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001; 37:S13-S19.
23. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001; 19:1327-1346.
24. Greenwood B, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet 1985; 81:536-538.
25. Guibourdenche M, Hoiby EA, Riou JY, et al. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 1996; 116:115-120.
26. World Health Organization. Meningococcal disease in Sudan. Communicable Disease Surveillance and Response. 2000. Available at: http//www.who.int/ disease-outbreak-news (accessed 8 October 2004).
27. World Health Organization. Meningococcal disease in Ethiopia. Communicable Disease Surveillance and Response. 2000. http//www.who.int/disease- outbreak-news (accessed 8 October 2004).
28. World Health Organization. Meningococcal disease in the African meningitis belt-update 4. 2001. http//www.who. int/disease-outbreak-news (accessed 8 October 2004).
29. Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002; 2:763-765.
30. Taha MK, Parent Du Chatelet I, Schlumberger M, et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002; 40:1083-1084.
31. Chonghaile C. Meningitis in Africa-tackling W135. Lancet 2002; 360:2054-2055.
32. Bhatt KM, Bhatt SM, Mirza NB. Meningococcal meningitis. East Afr Med J 1996; 73:35-39.
33. Achtman M. Clonal spread of serogroup A meningococci: a paradigm for the analysis of microevolution in bacteria. Mol Microbiol 1994; 11:15-22.
34. Achtman M, van der Ende A, Zhu P, et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg Infect Dis 2001; 7:420-427.
35. Moore PS, Reeves MW, Schwartz B, et al. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989; 2:260-263.
36. Cochi SL, Markowitz LE, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemiol 1987; 16:91-97.
37. Anonymous. Meningococcal disease. Wkly Epidemiol Rec 1995; 70:281-282.
38. Memish Z, Ahmed QAA. Mecca bound: the challenges ahead. J Travel Med 2002; 9:202-210.
39. Memish ZA. Infection control in Saudi Arabia: meeting the challenge. Am J Infect Control 2002; 30:57-65.
40. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob Agents 2003; 21:102-106.
41. al-Gahtani YM, el Bushra HE, al-Qarawi SM, et al. Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992. Epidemiol Infect 1995; 115:399-409.
42. Moore PS, Harrison LH, Telzak EE, et al. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988; 260:2686-2689.
43. Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000; 356:2159.
44. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 2002; 185: 1596-1605.
45. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679-683.
46. Hahne SJ, Gray SJ, Aguilera JF, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002; 359:582-583.
47. Issack MI, Ragavoodoo C. Hajj-related Neisseria meningitidis serogroup w135 in Mauritius. Emerg Infect Dis 2002; 8:332-334.
48. Fonkoua MC, Taha MK, Nicolas P, et al. Recent increase in meningitis caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. Emerg Infect Dis 2002; 8; 327-329.
49. Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitidis W-135 electrophoretic Type 37 during the Hajj, 2002. Emerg Infect Dis 2003; 9:734-737.
50. Caugant DA, Zollinger WD, Mocca LF, et al. Genetic relationships and clonal population structure of serotype 2 strains of Neisseria meningitidis. Infect Immun 1987; 55: 1503-1512.
51. Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997; 94:271-276.
52. MacLennan JM, Urwin R, Obaro S, et al. Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy? Lancet 2000; 356:1078.
53. Pollard AJ, Maiden MC. Epidemic meningococcal disease in sub-Saharan Africa-towards a sustainable solution? Lancet Infect Dis 2003; 3:68-70.
54. Pollard AJ, Shlim DR. Epidemic meningococcal disease and travel. J Travel Med 2002: 9:29-33.
55. Koch S, Steifen R. Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994; 1:4-7.
56. Turula VE, Kim J, Michon F, et al. An integrity assay for a meningococcal type B conjugate vaccine. Anal Biochem 2004; 327:261-270.
57. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282:417-420.
58. Makela PH, Kayhty H, Weckstrom P. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 1975; 2:883-886.
59. Greenwood BM, Wali SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; 1:729-732.
60. Hankins WA, Gwaltney JM Jr, Hendley JO, et al. Clinical and serological evaluation of meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med 1982; 169:54-57.
61. Al-Shamma SM, Al-Sa'ad MR. The persistence of antibodies induced by meningoccal polysaccharides of groups A and C in human volunteers. J Biol Stand 1987; 15:373-378.
62. Anonymous. Meningococcal vaccines. Product Information as of March 1994. MMWR 1985; 34:255-259.
63. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-874.
64. Hassan-King MKA, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988; 16:55-59.
65. Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999; 354: 615-616.
66. Zimmer SM, Stephens DS. Meningococcal conjugate vaccines. Expert Opin Pharmacother 2004; 5:855-863.
67. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367.
68. Offit PA, Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet 2004; 364:309-310.
69. Cano R, Larrauri A, Mateo S, et al. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 2004; 9(7). Available at: www.eurosurveillance.org/em/v09n07/0907- 223.asp
70. Mooney JD, Christie P, Robertson C, Clarke SC. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin Infect Dis 2004; 39:349-356.
71. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19:144-150.
72. Campbell JD, Edelman R, King JC Jr, et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186:1848-1851.
73. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23: 429-435.
74. Rennels M, King J Jr, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21:978-979.
75. Lewis R, Varaine F, Belanger F, et al. Control of meningococcal disease in west Africa. Lancet 2000; 355:1185-1186.
76. Centers for Disease Control and Prevention. Change in recommendation for meningococcal vaccine for travelers. MMWR 1999; 48:104.
77. Wilder-Smith A, Barkham TM, Paton NI. Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet 2002; 360:644-645.
78. Hahne S, Handford S, Ramsay M. W135 meningococcal carriage in Hajj pilgrims. Lancet 2002; 360:2089-2090.
79. Haelterman E, Boelaert M, Suetens C, et al. Impact of a mass vaccination campaign against a meningitis epidemic in a refugee camp. Trop Med Int Health 1996; 1:385-392.
80. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR07):11-20.
81. Wilder-Smith A, Barkham TM, Ravindran S, et al. Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts. Emerg Infect Dis 2003; 9:123-126.
82. Wilder-Smith A, Tai Goh K. W-135 meningococcal disease in a traveler: a case report. J Travel Med 2003; 10:59-60.
83. Wilder-Smith A, Paton NI. Crossover vaccination with quadrivalent meningococcal vaccine (against A/C/Y/W-135) following recent application of bivalent meningococcal vaccine (against A/C): assessment of safety and side effect profile. J Travel Med 2002; 9:20-23.
84. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999; 17:3086-3093.
85. Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004; 11:83-88.
86. Broker M. Vaccination against meningococcal disease: which vaccine to use? J Travel Med 2002; 9:168.